|
Abstract Objective To observe the clinical efficacy of fluvastatin combined with valsartan for the treatment of pa-tients with diabetic nephropathy (DN) and its impact on endothelial-1(ET-1) and calcitonin gene related peptide(CGRP) .[Methods]Totally 70 patients with DN were randomly divided into observation group and control group with 35 cases in each .On the basis of routine treatment ,the observation group received fluvastatin combined with valsartan ,while the control group received valsartan .The 24h quantitative urinary protein ,blood levels of ET-1 and CGRP ,clinical total effi-cacy and the incidence of adverse reaction were compared between two groups after 3 months .[Results] Compared with before treatment ,the 24h quantitative urinary protein and blood ET-1 in two groups after treatment were decreased ,but blood CGRP was increased ,and there was significant difference ( P<0 .05 or P<0 .01) .The improvement of above in-dexes in observation group was better than the control group ( P<0 .05) .The clinical total effective rate of observation group was better than that of the control group (91 .43% vs .74 .29% )( P<0 .05) .There was no significant difference in the incidence of adverse reactions between two groups ( P >0 .05) .[Conclusion]Fluvastatin combined with valsartan for the treatment of DN is safe and effective .The renal protective effect except lowing blood fat and blood pressure may be related to the regulation of ET-1 and CGRP in blood .
|
|
|
|
|
|
2014, Vol. 31 
